Nerviano Medical Sciences
  • Foto / Video
  • Contattaci
  • Lavorare in NMS
  • Cerca
  • English (UK)
  • Italiano (IT)
  • Home
  • NMS Company
    • Chi Siamo
    • Organi Statutari
    • Mission
    • News
      • Archivio
    • Storia e Track record
    • Licensing e Collaborazioni
    • Information Technology
    • Lavorare in NMS
    • Come Raggiungere NMS
    • Informazioni Legali
  • Oncology
    • About NMS Oncology
    • Intellectual Property
    • Pipeline
      • Nemorubicin
      • Danusertib
      • Milciclib
      • NMS-1116354
      • NMS-1286937
      • Preclinical Programs
    • Technology Platforms
      • Payloads and Antibody Drug Conjugates (ADCs)
    • Capabilities
      • Lead Optimization and Medicinal Chemistry
      • Fragment Based Drug Discovery
      • NMR Screening
      • Cell Assay Technologies
      • Cell Bank and Cell Proliferation
    • Collaborations
    • Science Corner
      • Eventi e Congressi
      • Pubblicazioni
      • Seminari di Oncologia
  • M.I.O.
    • Milano International Oncology
    • Expertise
    • Partnerships
    • Capabilities
    • Core services
  • Accelera
  • NerPharMa / DS

Archive

1 A new agreement has stated the official separation between Nerviano Medical Sciences and Pfizer. Giu 2, 2010
2 In JCO, Danusertib results of a Phase 1 trial. Phase 2 in patients with lung cancer and other solid tumors ongoing. Ott 8, 2009
3 FDA approves clinical studies of a novel anti-cancer drug developed by the Italian research Feb 10, 2009
4 Nerviano Medical Sciences announces a new Collaboration Agreement with Genentech to discover Antibody Drug Conjugates Ott 21, 2008
5 The DNDi Project of the Year: The Development of Fexinidazole to Treat "Sleeping Sickness". Giu 27, 2008
6 Three Nerviano Medical Sciences molecules at ASCO Giu 2, 2008
7 NMS DEVELOPS A NOVEL APPROACH FOR CANCER TREATMENT Mag 20, 2008
8 Pagina in manutenzione Mag 19, 2008
9 Students face to face with science Mag 13, 2008
10 Important new discoveries from NMS on Cdc7 inhibitor, a protein responsible for the proliferation of tumour cells Apr 15, 2008
  •  Inizio 
  •  Prec 
  •  1 
  •  2 
  •  Succ 
  •  Fine 

Pagina 1 di 2

NMS Company

  • Chi Siamo
  • Organi Statutari
  • Mission
  • News
    • Archivio
  • Storia e Track record
  • Licensing e Collaborazioni
  • Information Technology
  • Lavorare in NMS
  • Come Raggiungere NMS
  • Informazioni Legali
© Nerviano Medical Sciences - VAT No. 04379750963 | Viale Pasteur, 10 - 20014 Nerviano (MI) - Italy
  • Home
  • Termini di utilizzo
  • Credit